Hui Hao-Shen
University of Basel(CH)University Hospital of Basel(CH)
Publications by Year
Research Areas
Myeloproliferative Neoplasms: Diagnosis and Treatment, Chronic Myeloid Leukemia Treatments, Acute Myeloid Leukemia Research, Eosinophilic Disorders and Syndromes, Kruppel-like factors research
Most-Cited Works
- → Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms(2014)637 cited
- → Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice(2007)432 cited
- → Pf4-Cre transgenic mice allow the generation of lineage-restricted gene knockouts for studying megakaryocyte and platelet function in vivo(2006)414 cited
- → Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms(2010)173 cited
- → Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms(2019)125 cited
- → Loss of Ezh2 synergizes with JAK2 -V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis(2016)114 cited
- → Myeloproliferative neoplasms can be initiated from a single hematopoietic stem cell expressing JAK2 -V617F(2014)100 cited
- → JAK2-mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasms(2019)77 cited
- → Clonal analysis of deletions on chromosome 20q and JAK2-V617F in MPD suggests that del20q acts independently and is not one of the predisposing mutations for JAK2-V617F(2008)70 cited
- → Inhibition of interleukin-1β reduces myelofibrosis and osteosclerosis in mice with JAK2-V617F driven myeloproliferative neoplasm(2022)68 cited